Key Therapy Areas

Synexus has a world-class track record in many therapeutic areas, but retains a key strategic focus in five: Musculoskeletal, Cardiovascular, Diabetes and Metabolism, Respiratory, and CNS.

Musculoskeletal

Musculoskeletal studies accounted for 44% of our study profile last year.  Synexus specialises in large osteoporosis and arthritis studies where it is becoming increasingly difficult to find treatment naïve patients.  We also undertake studies in osteoarthritis, rheumatoid arthritis and more complicated areas.  Patient recruitment for such studies has been strongly supported by our relationships with local rheumatologists, orthopaedic specialists and primary care physicians.

Overall, we are consistently a top recruiter with nearly 300,000 patients within our musculoskeletal community, recruiting a total of over 10,000 patients across 160 studies, with the greatest contribution coming over the last 5 years.

Main Areas:

  • Ankylosing spondylitis
  • Gout
  • Osteoarthritis
  • Osteopenia
  • Osteoporosis
  • Rheumatoid Arthritis
  • Skeletal pain (knee, hip, lower back)
  • Tendonitis

Cardiovascular

Cardiovascular studies accounted for 40% of our study profile last year and we have considerable experience of large cardiovascular endpoint trials.

We have recruited over 12,000 patients at our research sites in the last three years, across 66 studies, supported  by our strong relationships with local cardiologists, cardiac rehabilitation centres and primary care physicians.  16% of patients in the Synexus community have cardiovascular diseases.

Our Strategic Advisory Board is led by Professor Mark Kearney.

Main areas:

  • Angina
  • Cardiac events & endpoint studies
  • Coronary artery disease
  • C-Reactive protein
  • Dyslipidemia
  • Heart Failure
  • Hypertension
  • Hypercholesterolaemia

Metabolic Disease & Diabetes

Synexus specialises in Type II diabetes studies with over 2,700 patients recruited in 88 studies in the past five years.. Diabetes patients have also been recruited into CV endpoint studies, helping to enrich our diabetic patient community.

We work constantly with local diabetologists, endocrinologists, primary care physicians and patient advocacy groups to support our recruitment efforts and have almost 100,000 diabetic patients involved in the Synexus community.

With a Scientific Advisory Board led by Professor Peter Grant and Dr Graham Ellis, in South Africa is a recognised Key Opinion Leader in diabetes and can take on a much broader range of diabetic patients.

Main Areas:

  • Type I diabetes
  • Type II diabetes
  • Diabetic foot ulcers
  • Diabetic neuropathy
  • Obesity
  • Endocrine disorders

Respiratory Disease

Synexus specialises in asthma and COPD research with over 3,000 patients recruited to 44 studies. We work with pulmonologists, respiratory physicians and primary care physicians who support our recruitment efforts.

We have over 140,000 patients with respiratory disease in the Synexus community.

Our Scientific Board is led by Professor Clive Page

Main Areas:

  • Allergy symptoms
  • Asthma
  • COPD
  • Smoking cessation
  • Sinusitis

CNS

This is a strategically important key therapeutic area, being developed in collaboration with the chairman of the Scientific Advisory Board, Professor Clive Ballard. Currently over 1,500 patients have been recruited in 47 studies.

89% of the Synexus patient community are aged over 50 and represent a strong source of older patients who would be good targets for cognitive health. This is being developed to identify patients for early cognitive impairment studies.  Synexus has considerable experience with pain study conduct and has the capacity to conduct psychiatry studies. 16% of patients in the Synexus community have CNS diseases.

Main Areas:

  • Anxiety
  • Early cognitive Impairment screening
  • Alzheimer’s disease
  • Dependency, alcohol
  • Depression
  • Insomnia
  • Migraine
  • Neuralgia
  • Neuropathic pain
  • Pain – lower back
  • Pain – knees and hips
  • Parkinson’s disease
  • Sexual dysfunction
  • Smoking cessation
  • Tinnitus


It has also been developing its capability in Dermatology, Consumer health, Vaccine and Gastroenterology.
Find out more about our emerging therapy areas